Annexon, Inc.
No enriched coverage for $ANNX in the last 7 days.
No SEC Form 4 filings for $ANNX in the last 30 days.
Annexon (NASDAQ:ANNX) announced earnings per share of ($0.32), meeting analyst expectations. The stock saw a slight dip to $4.96. Insider transactions were mixed with a director purchasing shares and an EVP selling, while hedge funds increased their holdings.
Annexon, Inc. (ANNX) has fully enrolled its Phase III ARCHER II trial for C1q inhibition in Geographic Atrophy (GA), with results anticipated in Q4. This novel approach aims to preserve vision by protecting photoreceptors, supported by strong functional and structural benefits observed in Phase II data. The trial is highly powered and aligned with regulators.
Annexon has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart to treat Guillain-Barré syndrome (GBS), marking a significant milestone for the company and patients. Tanruprubart is an investigational, first-in-class antibody designed to rapidly block classical complement-driven inflammation, with Phase 3 study results demonstrating faster and more complete recovery for GBS patients. The company also plans a Biologics License Application (BLA) submission with the FDA in 2026, building on data from the ongoing FORWARD study.
